Q32 Bio (QTTB) Restructuring Costs (2023)

Q32 Bio (QTTB) posted quarterly Restructuring Costs of $2.7 million for Q4 2023, down 59.53% quarter-over-quarter from $6.6 million in Q3 2023.

Q32 Bio (QTTB) Restructuring Costs (2023) Analysis & Trends

Q32 Bio's Restructuring Costs history runs 1 years deep, the most recent figure standing at $2.7 million for Q4 2023.

In Q4 2023, Restructuring Costs changed N/A year-over-year to $2.7 million; the TTM figure through Dec 2023 stood at $9.3 million (changed N/A YoY), while the FY2023 annual figure was $9.3 million, changed N/A from the prior year.
Restructuring Costs for Q4 2023 stood at $2.7 million, down from $6.6 million in the prior quarter.
The five-year high for Restructuring Costs was $6.6 million in Q3 2023, with the low at $2.7 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Q32 Bio	359.61 Mn	253.31 Mn	-

Download Data

Date	Value
Dec 31, 2023	2.69 Mn
Sep 30, 2023	6.64 Mn